BioNTech SE (BNTX)

166.96
+8.81(+5.57%)
After Hours
167.75
+0.79(+0.47%)
- Real-time Data
  • Volume:
    1,066,166
  • Day's Range:
    157.63 - 167.68
  • 52 wk Range:
    121.32 - 462.56

BNTX Overview

Prev. Close
158.15
Day's Range
157.63-167.68
Revenue
26.5B
Open
159.88
52 wk Range
121.32-462.56
EPS
54.63
Volume
1,066,166
Market Cap
40.46B
Dividend (Yield)
1.5342
(0.92%)
Average Vol. (3m)
1,539,372
P/E Ratio
2.90
Beta
-
1-Year Change
-21.85%
Shares Outstanding
243,019,216
Next Earnings Date
Aug 08, 2022
What is your sentiment on BioNTech?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

BioNTech SE Analysis

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
3082

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyNeutral
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral
  • 🚀🔆Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose.
    1
    • Covid is done, just like this stock. No movea will occur Until they produce something from their pipeline
      5
      • Coming soon I believe..
        1
    • 🚀 Great entry point for Therapeutics ready to release from the huge pipeline!
      2
      • covid globe it is best isn't it?
        3
        • 🚀 BioNTech submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as children ages 5 through <12).The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately 6 months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-µg two-dose primary series, which was authorized under EUA for this age group in October 2021. Data from this study demonstrated a strong immune response in this age group following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine with no new safety signals.
          1
          • BNTX will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.
            0
            • New variants will keep BNTX consistently developing, keeping the public guarded, and deriving steady revenue upsurges...
              1
              • rrrrright.....
                0
                • Bellow 100$ in summer
                  5
                  • sure sure... take that pill and RIP!
                    0
                • Rob Roo, you told everyone to buy when it was 350. Pathetic.
                  3
                  • You're a big boy, you can make your own decisions...
                    2